Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE PORTERFIELD

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1962451377
CMS profile
315523
Location
PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$238.66

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $225.35 13
Education $13.31 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE PORTERFIELD

NPI 1962451377 · CMS profile ID 315523

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PANAMA CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962451377?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE PORTERFIELD, NPI 1962451377, CMS profile ID 315523. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962451377?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRUCE PORTERFIELD, NPI 1962451377, CMS profile ID 315523. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962451377?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRUCE PORTERFIELD, NPI 1962451377, CMS profile ID 315523, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1962451377?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $238.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $15.3810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719065105 CMS
Lilly USA, LLC $12.6808/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728360427 CMS
E.R. Squibb & Sons, L.L.C. $13.3107/09/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727924459 CMS
Janssen Biotech, Inc. $21.5907/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719065103 CMS
Seagen Inc. $13.2106/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732436159 CMS
Janssen Biotech, Inc. $23.6805/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719065101 CMS
Lilly USA, LLC $17.6403/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357061 CMS
Blueprint Medicines Corporation $19.4003/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750717535 CMS
Novartis Pharmaceuticals Corporation $11.9502/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726084141 CMS
Karyopharm Therapeutics Inc. $20.7502/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751732979 CMS
Kite Pharma, Inc. $17.7502/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731504351 CMS
PFIZER INC. $13.8202/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743701133 CMS
AstraZeneca Pharmaceuticals LP $22.1802/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736176433 CMS
AstraZeneca Pharmaceuticals LP $15.3201/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736056397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,052.28 56
PY2020 $238.66 14
PY2021 $127.80 3
PY2023 $29.35 2
PY2024 $241.81 12
PY2025 $785.94 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $32,674.28 6
PY2021 Principal investigator $35,299.16 56
PY2020 Principal investigator $29,264.42 31
PY2019 Principal investigator $53,190.35 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/07/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816783029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/07/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816783039
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/07/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816783051
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $550.00 11/26/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816779706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 11/23/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816779369
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $975.00 11/23/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816779379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $350.00 11/23/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816779389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $725.00 11/09/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816774909
Principal investigator 1 EMD Serono, Inc. $1,236.00 11/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842917985
Principal investigator 1 EMD Serono, Inc. $503.00 11/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842918043
Principal investigator 1 EMD Serono, Inc. $1,000.00 11/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842918125
Principal investigator 1 EMD Serono, Inc. $345.00 10/14/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842918921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,825.00 09/17/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816760257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/14/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816759455
Principal investigator 1 EMD Serono, Inc. $1,105.00 09/09/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842913395
Principal investigator 1 EMD Serono, Inc. $57.00 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842904943
Principal investigator 1 EMD Serono, Inc. $220.60 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842908461
Principal investigator 1 EMD Serono, Inc. $104.00 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842908467
Principal investigator 1 EMD Serono, Inc. $413.00 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842908607
Principal investigator 1 EMD Serono, Inc. $467.00 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842911437
Principal investigator 1 EMD Serono, Inc. $470.00 08/26/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842911527
Principal investigator 1 EMD Serono, Inc. $865.00 08/10/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842908917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 07/02/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816737095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $240.72 06/01/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816729119
Principal investigator 1 EMD Serono, Inc. $50.00 05/21/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842925825
Principal investigator 1 EMD Serono, Inc. $565.00 05/13/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842926803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 05/07/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816720701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.00 05/07/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816720711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 04/27/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816716653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $725.00 04/27/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816716663
Principal investigator 1 EMD Serono, Inc. $1,250.00 04/06/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842924483
Principal investigator 1 EMD Serono, Inc. $540.00 04/06/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842924571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $240.72 04/01/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816705521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701150
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,475.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701179
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $350.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701219
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701229
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701245
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35.00 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $517.12 03/18/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816701265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $550.00 02/23/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816692247
Principal investigator 1 EMD Serono, Inc. $630.00 02/19/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842898989
Principal investigator 1 EMD Serono, Inc. $370.00 02/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842898847
Principal investigator 1 EMD Serono, Inc. $300.00 02/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842902059
Principal investigator 1 EMD Serono, Inc. $250.00 02/02/2021 Non-covered Recipient Entity
ACRC ARIZONA CLINICAL RESEARCH CENTER
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842907009
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,400.00 01/28/2021 Non-covered Recipient Entity
Acrc/arizona Clinical Research Center, Incorporated
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma No dispute reported 06/30/2026 819891063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 01/08/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816679255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $350.00 01/08/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816679265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 01/08/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816679275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 01/05/2021 Non-covered Recipient Entity
ARIZONA CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA No dispute reported 06/30/2026 816677311